CE Holdings (4320) Q4 2026 earnings summary

Executive summary

• FY ended Sep 2026 revenue rose 2.2% to ¥16,173m, operating profit rose 2.6% to ¥1,447m and ordinary profit rose 3.9% to ¥1,481m, all record highs.

• Net income attributable to owners of the parent fell 51.4% to ¥756m from ¥1,557m; FY2025 included a ¥873m gain from share sales, while FY2026 included a ¥148m impairment loss.

• Operating and ordinary profit increased despite tender-offer costs, supported by higher electronic medical record system sales.

Financial highlights

• Gross profit increased to ¥3,779m from ¥3,581m; SG&A rose to ¥2,331m from ¥2,169m.

• Operating cash flow was ¥2,177m versus ¥986m; investing and financing cash outflows were ¥812m and ¥1,518m, respectively.

• Cash and cash equivalents ended FY2026 at ¥4,880m, down from ¥5,032m.

• Total assets declined to ¥11,410m from ¥12,746m, and total liabilities fell to ¥2,631m from ¥3,904m.

Segment performance

• Healthcare Solutions revenue was ¥15,684m, up 2.3%; segment profit was ¥1,608m, up 10.6%.

• Marketing Solutions revenue was ¥488m, down 2.7%; segment profit improved to ¥17m from a ¥8m loss.

• Consolidated orders were ¥13,997m, down 13.3%, and backlog was ¥4,152m, down 23.9%, as large projects progressed to revenue recognition.